Active Filter(s):
Details:
CSMC has decided discontinue the trial and will conduct a comprehensive review of the final data set, based on the review of the interim analysis. SYN-010 was well-tolerated but it is unlikely to meet its primary objective by the time enrollment is completed.
Lead Product(s): Lovastatin Lactone
Therapeutic Area: Gastroenterology Product Name: SYN-010
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020